AROMA inclusion and exclusion criteria
| Inclusion criteria |
| Patients aged ≥18 years at initiation |
| All patients who are newly initiated on dupilumab for the treatment of chronic rhinosinusitis with nasal polyps according to the country-specific prescribing information (product label or summary of product characteristics) |
| Willing and able to comply with clinic visits and study-related procedures as per protocol |
| Provide informed consent signed by study patient or legally acceptable representative |
| Able to understand and complete study-related questionnaires as per protocol |
| Exclusion criteria |
| Patients who have a contraindication to dupilumab according to the country-specific prescribing information |
| Any previous treatment with dupilumab for any condition |
| Any condition that, in the opinion of the investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other medical, social or personal conditions and circumstances that can predictably prevent the patient from adequately completing the schedule of visits and assessments |
| Participation in an ongoing interventional or observational study that might, in the treating physician's opinion, influence the assessments for the current study |
| Parallel inclusion in another Sanofi-independent registry might be possible if the patient gives consent |